Comparative Pharmacology
Head-to-head clinical analysis: CIPRO IN DEXTROSE 5 IN PLASTIC CONTAINER versus MAXAQUIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO IN DEXTROSE 5 IN PLASTIC CONTAINER versus MAXAQUIN.
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER vs MAXAQUIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
400 mg intravenously every 8-12 hours over 60 minutes.
400 mg orally once daily for 5-10 days; for complicated urinary tract infections, 400 mg orally once daily for 10-14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 4 hours (range 3-7 hours) in patients with normal renal function; extends to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 12 hours (range 10-14 hours), supporting twice-daily dosing for systemic infections.
Renal excretion of unchanged drug accounts for approximately 50% of elimination, with 15% as metabolites; biliary/fecal excretion contributes about 20-35%.
Renal excretion of unchanged drug accounts for 70-80%; biliary/fecal elimination accounts for 20-30%.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic